Drug
Mepolizumab 300 mg
Mepolizumab 300 mg is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_4
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)
Trials by Status
completed267%
enrolling_by_invitation133%
Recent Activity
0 active trials
Showing 3 of 3
enrolling_by_invitationphase_4
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
NCT07343661
completedphase_2
Mepo for Eosinophilic Esophagitis (EoE) Study
NCT03656380
completedphase_3
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
NCT02836496
Clinical Trials (3)
Showing 3 of 3 trials
NCT07343661Phase 4
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
NCT03656380Phase 2
Mepo for Eosinophilic Esophagitis (EoE) Study
NCT02836496Phase 3
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3